RVTY
Revvity, Inc.96.27
-2.81-2.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
11.17BP/E (TTM)
49.62Basic EPS (TTM)
1.94Dividend Yield
0%Recent Filings
8-K
Revvity appoints new CAO
Revvity appointed Anita Gonzales as Vice President and Chief Accounting Officer on October 23, 2025, effective immediately. The 49-year-old CPA, who joined as Vice President and Controller in May 2023, brings a decade of experience from General Electric in audit and controllership, plus prior roles at PwC. This internal promotion bolsters financial oversight amid ongoing operations. No compensation details disclosed.
10-Q
Q2 FY2025 results
Revvity posted Q2 revenue of $720.3M, up 4% y/y from $691.7M, with Life Sciences gaining 5% on software strength and Diagnostics edging 3% higher in immunodiagnostics and reproductive health. Gross margin slipped to 54.5% from 55.7%, hit by tariffs and mix shifts, yet operating income climbed 6% y/y to $90.8M on leverage and productivity. Diluted EPS held at $0.46, matching last year, while YTD figures show revenue up 3% to $1.385B and EPS steady at $0.81. Cash dipped to $991.8M after $447.5M in buybacks, but $1.5B revolver capacity cushions liquidity against $3.2B debt. Tariffs sting, but pricing offsets much of it. Solid footing amid headwinds. Buybacks signal confidence.
8-K
Revvity Q2 revenue up 4%
Revvity reported Q2 2025 revenue of $720 million, up 4% reported and 3% organic from last year, with Life Sciences growing 5% and Diagnostics 3%. GAAP EPS from continuing operations hit $0.47, while adjusted EPS dipped to $1.18 amid higher costs; margins slipped slightly to 26.6%. The company raised full-year guidance to $2.84-$2.88 billion in revenue and $4.85-$4.95 adjusted EPS, signaling confidence despite market headwinds. Execution trumps volatility.
10-Q
Q1 FY2025 results
Revvity kicked off fiscal 2025 with revenue climbing 2% year-over-year to $664.8 million for the quarter ended March 30, 2025, fueled by 3% growth in Diagnostics while Life Sciences edged up 1% on software gains offsetting solutions dips. Gross margins expanded 186 basis points to 56.5%, lifting operating income 64% to $72.2 million and diluted EPS from continuing operations 52% to $0.35, reconciled against 120,233 weighted shares with no anti-dilution flags. Cash from operations dipped to $134.1 million, yielding free cash flow of $118.1 million after $16.0 million capex (derived), yet $1.14 billion in cash bolsters liquidity alongside a $1.5 billion revolver through 2030 and $3.17 billion in fixed-rate debt. Share repurchases hit $153.6 million, trimming shares outstanding. Tariffs pose a headwind, potentially trimming operating income by $20 million this year.
8-K
Revvity Q1 beats expectations
Revvity reported Q1 2025 revenue of $665 million, up 2% reported and 4% organically from $650 million a year ago, with adjusted EPS from continuing operations rising to $1.01 from $0.98. Life Sciences revenue grew 1% to $340 million, while Diagnostics surged 3% to $324 million, though its adjusted margin dipped to 22.8% from 24.3%. Strong execution beat expectations. The company reaffirmed 3-5% full-year organic growth and $4.90-$5.00 adjusted EPS guidance amid macroeconomic shifts.
IPO
Website
Employees
Sector
Industry
BDSX
Biodesix, Inc.
7.90+0.38
CRL
Charles River Laboratories Inte
195.22-2.93
DGX
Quest Diagnostics Incorporated
178.66-5.45
ILMN
Illumina, Inc.
131.56-3.36
IQV
IQVIA Holdings, Inc.
221.68-1.95
NOTV
Inotiv, Inc.
0.68-0.02
QDEL
QuidelOrtho Corporation
28.88-0.18
QGEN
Qiagen N.V.
45.01-0.43
TMO
Thermo Fisher Scientific Inc
570.16-5.75
TWST
Twist Bioscience Corporation
31.13+0.06